RedHill Biopharma

375 articles with RedHill Biopharma

• RedHill Biopharma Ltd. Reports Positive PK Clinical Studies Towards Planned NDA with RHB-102 (Anti-Emetic)

  10/8/2013

• RedHill Biopharma Ltd. Initiates Phase III Study of RHB-104 for Crohn's Disease

  10/1/2013

• RedHill Biopharma Ltd. to Present at the Annual BioPharm America International Partnering Conference

  9/11/2013

• RedHill Biopharma Ltd. to Present at the Stifel Nicolaus Annual Healthcare Conference

  9/3/2013

• Bioassociate Reiterated PT on RedHill Biopharma Ltd. Following Q2 Report

  8/21/2013

• RedHill Biopharma Ltd. Announces Positive European Regulatory Meetings Regarding Its European Phase III Plan for RHB-104 (Crohn's)

  8/20/2013

• RedHill Biopharma Ltd. Announces Positive Pre-Clinical Rheumatoid Arthritis Results With RHB-104 and Plans for a Phase IIa Study

  7/30/2013

• RedHill Biopharma Ltd. Reports Results for the Second Quarter of 2013

  7/23/2013

• RedHill Biopharma Ltd. Provides Update on Planned NDA Filing for RHB-102 (Once Daily Anti-Emetic) in Q1 2014 and Commences PK Program

  7/11/2013

• RedHill Biopharma Ltd. to Present at the JMP Securities Annual Healthcare Conference in New York

  7/3/2013

• RedHill Biopharma Ltd. Announces FDA Acceptance for Review of RHB-103 NDA for Acute Migraine and PDUFA Goal Date of February 3, 2014

  6/18/2013

• RedHill Biopharma Ltd. Commences Patient Screening in a Phase IIa Clinical Trial With RHB-104 for Multiple Sclerosis

  6/5/2013

• RedHill Biopharma Ltd. Announces Positive FDA Meeting Regarding the Regulatory Path Towards NDA Submission of RHB-101 for the Treatment of Congestive Heart Failure and Hypertension

  5/29/2013

• RedHill Biopharma Ltd. to Present at the Jefferies and Co. 2013 Global Healthcare Conference in New York

  5/28/2013

• RedHill Biopharma Ltd. Submits New Drug Application to U.S. FDA for RHB-103 Anti-Migraine Oral Thin Film

  3/27/2013

• RedHill Biopharma Ltd. Receives Positive Feedback From a Scientific Advice Meeting in Europe Regarding RHB-101 (Hypertension) Marketing Application Plan

  3/19/2013

• RedHill Biopharma Ltd. to Present at the 25th Annual ROTH Conference

  3/6/2013

• RedHill Biopharma Ltd. Reports 2012 Fourth Quarter And Year-End Results

  2/20/2013

• RedHill Biopharma Ltd. Announces Issuance of New U.S. Patent and Provides Update on RHB-104 for Treatment of Crohn's Disease

  1/7/2013

• RedHill Biopharma Ltd. Announces NASDAQ Listing and Commencement of Trading Under the Ticker "RDHL"

  12/27/2012